+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 130 Pages
  • January 2025
  • Region: Global
  • Grand View Research
  • ID: 6052199
Description Jump to:
The global guillain-Barre syndrome market size is anticipated to reach USD 1.03 billion by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period. The increasing prevalence of Guillain-Barré Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights

  • Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barré Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG’s proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.
  • Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.
  • Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.
  • North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region’s strong focus on research and innovation further supports market growth.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Increasing prevalence of Guillain-Barré Syndrome (GBS)
3.3.1.2. Government regulations and guidelines
3.3.1.3. Advancements in treatment options
3.3.2. Market Restraints Analysis
3.3.2.1. Side effects and adverse reactions
3.3.2.2. High cost treatment
3.4. Guillain-Barre Syndrome Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis
4.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
4.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
4.3. Intravenous Immunoglobulin (IVIG)
4.3.1. Intravenous Immunoglobulin (IVIG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Plasma Exchange
4.4.1. Plasma Exchange Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Others
4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis
5.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
5.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
5.3. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
5.3.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
5.4.1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Miller Fisher Syndrome (MFS)
5.5.1. Miller Fisher Syndrome (MFS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Acute Motor Axonal Neuropathy (AMAN)
5.6.1. Acute Motor Axonal Neuropathy (AMAN) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other
5.7.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis
6.1. Guillain-Barre Syndrome Market: Route of Administration Segment Dashboard
6.2. Guillain-Barre Syndrome Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
6.3. Parenteral
6.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis
7.1. Guillain-Barre Syndrome Market: Distribution Channel Segment Dashboard
7.2. Guillain-Barre Syndrome Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
7.3. Hospital Pharmacies
7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail Pharmacies
7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Other Pharmacies
7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis
8.1. Guillain-Barre Syndrome Market Share, By Region, 2024 & 2030, USD Million
8.2. North America
8.2.1. North America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Norway
8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. China
8.4.2.1. China Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Japan Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. South Korea Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Australia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2017 - 2030 (USD Million)
8.6.2. Saudi Arabia
8.6.2.1. Saudi Arabia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. UAE
8.6.3.1. UAE Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. Kuwait
8.6.4.1. Kuwait Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Africa
8.6.5.1. South Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis, 2024
9.5. Company Profiles
9.5.1. AbbVie Inc.
9.5.1.1. Participant’s Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Recent Developments/ Strategic Initiatives
9.5.2. Biogen
9.5.2.1. Participant’s Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Recent Developments/ Strategic Initiatives
9.5.3. Cadila Pharmaceuticals
9.5.3.1. Participant’s Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Recent Developments/ Strategic Initiatives
9.5.4. CSL
9.5.4.1. Participant’s Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Recent Developments/ Strategic Initiatives
9.5.5. F. Hoffmann-La Roche Ltd.
9.5.5.1. Participant’s Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Recent Developments/ Strategic Initiatives
9.5.6. GSK plc.
9.5.6.1. Participant’s Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Recent Developments/ Strategic Initiatives
9.5.7. Grifols S.A.
9.5.7.1. Participant’s Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Recent Developments/ Strategic Initiatives
9.5.8. LGM Pharma.
9.5.8.1. Participant’s Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Recent Developments/ Strategic Initiatives
9.5.9. Merck & Co., Inc.
9.5.9.1. Participant’s Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Recent Developments/ Strategic Initiatives
9.5.10. Octapharma AG
9.5.10.1. Participant’s Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Recent Developments/ Strategic Initiatives
9.5.11. Pfizer Inc.
9.5.11.1. Participant’s Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Recent Developments/ Strategic Initiatives
9.5.12. Takeda Pharmaceutical Company Limited
9.5.12.1. Participant’s Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 4 Global Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 5 Global Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 8 North America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 9 North America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 North America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 U.S. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 12 U.S. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 13 U.S. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 14 U.S. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 15 Canada Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 16 Canada Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 17 Canada Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 18 Canada Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Mexico Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 20 Mexico Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 21 Mexico Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 Mexico Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Europe Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 24 Europe Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 25 Europe Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 26 Europe Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Germany Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 28 Germany Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 29 Germany Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 30 Germany Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 31 U.K. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 32 U.K. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 33 U.K. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 U.K. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 France Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 36 France Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 37 France Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38 France Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 39 Italy Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 40 Italy Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 41 Italy Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 42 Italy Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Spain Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 44 Spain Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 45 Spain Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 46 Spain Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Denmark Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 48 Denmark Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 49 Denmark Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 50 Denmark Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Sweden Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 52 Sweden Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 53 Sweden Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 54 Sweden Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Norway Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 56 Norway Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 57 Norway Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 58 Norway Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 China Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 64 China Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 65 China Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 66 China Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Japan Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 68 Japan Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 69 Japan Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 70 Japan Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 71 India Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 72 India Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 73 India Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 74 India Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 75 South Korea Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 76 South Korea Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 77 South Korea Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 78 South Korea Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 79 Australia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 80 Australia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 81 Australia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 82 Australia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Thailand Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 84 Thailand Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 85 Thailand Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 86 Thailand Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 87 Latin America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 88 Latin America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 89 Latin America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 90 Latin America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 91 Brazil Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 92 Brazil Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 93 Brazil Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 94 Brazil Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 95 Argentina Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 96 Argentina Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 97 Argentina Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 98 Argentina Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 100 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 101 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 102 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 103 South Africa Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 104 South Africa Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 105 South Africa Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 106 South Africa Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 111 UAE Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 112 UAE Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 113 UAE Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 114 UAE Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 115 Kuwait Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 116 Kuwait Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 117 Kuwait Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 118 Kuwait Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Guillain-Barre syndrome market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook, 2024 (USD billion)
Fig. 11 Market trends & outlook
Fig. 12 Porter’s five force analysis
Fig. 13 PESTEL analysis
Fig. 14 Guillain-Barre Syndrome market: Therapeutics outlook and key takeaways
Fig. 15 Guillain-Barre Syndrome market: Therapeutics movement analysis
Fig. 16 Intravenous Immunoglobulin (IVIG) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Plasma Exchange market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Guillain-Barre Syndrome market: Type outlook and key takeaways
Fig. 20 Guillain-Barre Syndrome market: Type movement analysis
Fig. 21 Acute Inflammatory Demyelinating Polyneuropathy (AIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Miller Fisher Syndrome (MFS) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Acute Motor Axonal Neuropathy (AMAN) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Guillain-Barre Syndrome market: Route of administration outlook and key takeaways
Fig. 27 Guillain-Barre Syndrome market: Route of administration movement analysis
Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Parenteral market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Guillain-Barre Syndrome market: Distribution channel outlook and key takeaways
Fig. 31 Guillain-Barre Syndrome market: Distribution channel movement analysis
Fig. 32 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Other pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Regional Marketplace: Key Takeaways
Fig. 36 Regional Outlook, 2024 & 2030
Fig. 37 Global Guillain-Barre syndrome market, Region Movement Analysis
Fig. 38 North America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 39 U.S. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 40 Canada Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 41 Mexico Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 42 Europe Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 43 Germany Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 44 U.K. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 45 France Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 46 Italy Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 47 Spain Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 48 Denmark Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 49 Sweden Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 50 Norway Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 52 Japan Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 53 China Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 54 India Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 55 Australia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 56 South Korea Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 57 Thailand Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 58 Latin America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 59 Brazil Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 60 Argentina Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 61 Middle East and Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 62 South Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 64 UAE Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 65 Kuwait Guillain-Barre syndrome market, 2018 - 2030 (USD Million)

Companies Mentioned

  • AbbVie Inc.
  • Biogen
  • Cadila Pharmaceuticals
  • CSL
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Grifols S.A.
  • LGM Pharma
  • Merck & Co., Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages130
PublishedJanuary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 0.73 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.03 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Guillain-Barre Syndrome Therapeutics - Global Strategic Business Report - Product Image

Guillain-Barre Syndrome Therapeutics - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Guillain-Barre Syndrome Treatment Market Report and Forecast 2024-2032 - Product Image

Guillain-Barre Syndrome Treatment Market Report and Forecast 2024-2032

  • Report
  • 240 Pages
  • Global
From
Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Guillain-Barre Syndrome (GBS) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 233 Pages
  • Global
From
Guillain-Barre Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Guillain-Barre Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.